Physician profile
Anna E Cottle
NPI 1851691059
$4,954.36
in general payments reported to CMS, 2019-2025
21 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $538 · 2022: $889 · 2023: $828 · 2024: $1,348 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,369 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,368.60 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,082.29 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $837.27 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $746.52 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $532.45 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $478.48 | 2021-2024 | Zeposia |
| Genzyme Corporation | $309.45 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $177.44 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $110.40 | 2024-2025 | Iqirvo |
| Janssen Scientific Affairs, LLC | $108.21 | 2021 | |
| Phathom Pharmaceuticals, INC. | $93.05 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $86.62 | 2024-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $62.58 | 2022-2025 | Linzess |
| Madrigal Pharmaceuticals | $59.98 | 2025 | Rezdiffra |
| Vivus LLC | $46.64 | 2024 | Qsymia |
| Ardelyx, INC. | $46.56 | 2023-2025 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41.11 | 2022 | |
| Gilead Sciences, INC. | $36.10 | 2022-2024 | |
| Novo Nordisk INC | $32.02 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Aimmune Therapeutics, INC. | $26.77 | 2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $24.57 | 2021 | |
| Lilly USA, LLC | $15.85 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Cottle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.